Lung cancer is associated with high prevalence and mortality, and despite significant successes with targeted drugs in genomically defined subsets of lung cancer and immunotherapy, the majority of patients currently does not benefit from these therapies. Through a targeted drug screen, we found the ...
Metastasis poses a major challenge in cancer management, including EML4-ALK-rearranged non-small cell lung cancer (NSCLC). As cell migration is a critical step during metastasis, we assessed the anti-migratory activities of several clinical ALK inhibitors in NSCLC cells and observed differential ant...
Here, we have determined rhGAA ADA epitopes in the plasma samples of Pompe disease patients using series of affinity purifications combined with epitope extraction and label free quantitation LC-MS methodology
Here we set out to identify protein targets of Lipoic acid and Lipoamide by chemical proteomics approaches. We generated Lipoamide-based affinity matrices to pulldown target proteins and quantify them via bottom-up proteomics. Use of the same affinity matrix in dose dependent compeition assays allow...
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. Here, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between the MEK i...
PARP1 inhibitors (PARP1is) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, o...
